Clinical Aspects of Fertility Preservation in Female Patients

被引：24

作者：

Wallberg, Kenny A. Rodriguez-Macias ^{[1
,2
]}

Keros, Victoria ^{[1
,2
]}

Hovatta, Outi ^{[1
,2
]}

机构：

[1] Karolinska Univ Hosp, Fertil Unit, Div Obstet & Gynecol, SE-14186 Stockholm, Sweden

[2] Karolinska Inst, Dept Clin Sci Technol & Intervent, Stockholm, Sweden

来源：

PEDIATRIC BLOOD & CANCER | 2009年 / 53卷 / 02期

关键词：

cancer; chemotherapy; cryopreservation; fertility preservation; ovarian tissue; CRYOPRESERVED OVARIAN TISSUE; HUMAN OOCYTE CRYOPRESERVATION; IN-VITRO MATURATION; LONG-TERM CULTURE; CANCER-PATIENTS; PRIMORDIAL FOLLICLES; CELL CONTAMINATION; HORMONE AGONIST; BREAST-CANCER; HUMAN-EMBRYOS;

D O I：

10.1002/pbc.21995

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There are several methods of fertility preservation available for female patients facing infertility following gonadotoxic treatment of cancer or systemic disease. Embryos, oocytes or ovarian tissue can be cryopreserved and stored until the time when the patient is Cured of her main disease and is expecting parenthood. The individual's choice depends on the nature and stage of the main disease, expected treatment, their condition, and age and existence of the partner. It is important to inform all such women about the options, and together with them, choose the most appropriate ones. It is often possible to save ovarian tissue even though the first chemotherapy Courses have been undergone, but many more follicles can be stored before cancer treatment. Pediatr Blood Cancer 2009;53:254-260. (C) 2009 Wiley-Liss, Inc.

引用

页码：254 / 260

页数：7

共 68 条

[1] Selection of patients before and after anticancer treatment for ovarian cryopreservation [J].